Ian James Welsby
Professor of Anesthesiology

As a practicing cardiothoracic anesthesiologist, I have contributed to the better understanding of the management and of perioperative thrombosis (particularly HIT). This has been as a Duke site PI for the Rare Thrombotic Diseases Consortium led by Dr T.L Ortel and a clinical collaborator with the basic and translational science approach to HIT led by Dr G Arepally. I have also championed novel approaches to dealing with perioperative HIT such as plasmaperesis.

Similarly, I have been a local leader in establishing management of transfusion approaches to major cardiac surgery including the novel introduction of autologous plateletpheresis to limit exposure to allogeneic platelet transfusions in this highly transfused population, identifying the transfusion requirements during thoracic aortic reconstruction and promoting use of a lower dose of rFVIIa use in this population, changing established clinical practice.

My research interests focus on perioperative transfusion and hematology concerns. Recently, Dr Kor (Mayo Clinic) and I received a multiple PI R-01 award to evaluate point-of-care/bedside washing of packed red blood cells to reduce perioperative lung injury. This novel repurposing of commonly available “cell-saver” technology is, for most surgical cases, the only practical means of delivering a washed product, and promises to be a critical advancement in perioperative transfusion medicine. I also have a longstanding interest in the rejuvenation of RBCs to normalize oxygen delivery capacity of transfused RBCs. Such a development will be of tremendous importance to transfusion practice, particularly for highly transfused populations. 

In summary, I have dedicated my research career to improving the outcome of patients undergoing cardiothoracic surgery, understanding perioperative coagulopathy, and optimizing transfusion practice. 

Current Research Interests

Elucidating factors predisposing to thrombotic or hemorrhagic complications and adverse outcomes related to transfusion after cardiac surgery. Utilizing outcomes data after cardiac surgery to optimize transfusion safety in this patient group.

The clinical implications of the generation of antibodies to the composite heparin/platelet factor 4 antigen and the management of heparin induced thrombocytopenia (HIT), in collaboration with Dr TL Ortel, Duke Hematology, and exploring alternative anticoagulant regimens to improve anticoagulation during and after cardiac surgery for patients with HIT.

Improving the outcome associated with blood product transfusion in the cardiac surgical patient by developing techniques of microparticle elimination prior to RBC transfusion and autologous platelet harvest during cardiac surgery.

Current Appointments & Affiliations

Contact Information

  • 2301 Erwin Road, 5691H Hafs Building, Durham, NC 27710
  • Box 3094 Med Ctr, Durham, NC 27710

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.